"Adial's collaboration with Cytel reinforces our commitment to disciplined capital deployment and data-driven execution," said Cary Claiborne, CEO at Adial. "By leveraging advanced analytics and adaptive design, we are in a strong position to generate meaningful clinical data while minimizing time and spend. We believe this strategy materially increases the probability of success for AD04 and creates significant value for patients and shareholders alike." Adial's platform is focused on developing geneticall ...

To register to attend BIO 2025, visit convention.bio.org. About BIO FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The ...

Core Insights - Tempus AI, Inc. (NASDAQ: TEM) is a technology company focused on precision medicine, primarily in genomics and data services, with a recent expansion into AI applications for healthcare [1] Company Overview - The company's core business revolves around genomics and data services, which has shown impressive growth [1] - Tempus AI is now integrating artificial intelligence into its healthcare solutions, indicating a strategic shift towards advanced technology applications [1] Growth and Expansion - The expansion into AI for healthcare applications has contributed to the company's growth trajectory, highlighting its commitment to innovation in the medical field [1]

Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products ...

Bio-Techne (TECH) FY Conference June 03, 2025 03:40 PM ET Speaker0 Thanks everyone for hanging with us towards the end of the day here. And thanks for joining us for the Biotechnology Management Presentation. My name is Matt Larue. Very happy to have CEO Kim Kelderman here and Dave Claire from IR is here as well. So thanks to them for joining us. I have two logistical comments. One, the breakout is in Maher on the Second Floor. And then second, for a list of our research disclosures and conflicts of interes ...

Key Takeaways QGEN partners with Tracer and Foresight to advance MRD testing in oncology clinical trials. New alliances support decentralized, non-invasive diagnostics using QIAGEN's QIAcuity dPCR and ctDNA tests. The partnerships aim to broaden clinical access and enhance QGEN's leadership in personalized cancer care.QIAGEN N.V. (QGEN) announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics ...

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physi ...

Core Insights - Telix Pharmaceuticals Limited is hosting an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in precision medicine and therapeutic radiopharmaceuticals [1][4] Company Overview - Telix is a biopharmaceutical company dedicated to developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in the U.S., Brazil, Canada, Europe, and Japan [4] - The company is addressing significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products [4] Event Details - The Investor Day will feature key opinion leaders discussing the clinical utility and opportunities for Telix's theranostic candidates [2] - In-person attendance is available for institutional investors and analysts, with advance registration required [3] Key Opinion Leaders - Dr. Oliver Sartor, an expert in prostate cancer, will discuss TLX591, having published over 500 peer-reviewed articles and led pivotal Phase 3 studies [7] - Dr. John de Groot, a neuro-oncology expert, will present on TLX101, with over 200 peer-reviewed publications and significant involvement in clinical studies [7] - Dr. Joseph Osborne, specializing in renal cancer imaging, will cover TLX250-CDx, focusing on advancing molecular imaging [7]

Shares of Tempus AI (TEM 14.71%) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (^GSPC 0.41%) and the Nasdaq Composite (^IXIC 0.67%) jumped 0.4% and 0.6%, respectively.Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report last week alleging, among other things, that Tempus is overstating its use of AI. On Friday and Saturday, the company made announcements regarding tw ...

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery pro ...